JPH07507440A - 結合親和性を高めた抗体構築物 - Google Patents

結合親和性を高めた抗体構築物

Info

Publication number
JPH07507440A
JPH07507440A JP3505551A JP50555191A JPH07507440A JP H07507440 A JPH07507440 A JP H07507440A JP 3505551 A JP3505551 A JP 3505551A JP 50555191 A JP50555191 A JP 50555191A JP H07507440 A JPH07507440 A JP H07507440A
Authority
JP
Japan
Prior art keywords
construct
antibody
region
binding
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP3505551A
Other languages
English (en)
Japanese (ja)
Inventor
ジリーズ,スティーヴン・ディー
Original Assignee
レプリゲン・コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レプリゲン・コーポレーション filed Critical レプリゲン・コーポレーション
Publication of JPH07507440A publication Critical patent/JPH07507440A/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP3505551A 1990-03-02 1991-01-30 結合親和性を高めた抗体構築物 Pending JPH07507440A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48829790A 1990-03-02 1990-03-02
US488,297 1990-03-02
PCT/US1991/000633 WO1991013166A1 (fr) 1990-03-02 1991-01-30 Constructions d'anticorps ayant une affinite de liaison amelioree

Publications (1)

Publication Number Publication Date
JPH07507440A true JPH07507440A (ja) 1995-08-24

Family

ID=23939159

Family Applications (1)

Application Number Title Priority Date Filing Date
JP3505551A Pending JPH07507440A (ja) 1990-03-02 1991-01-30 結合親和性を高めた抗体構築物

Country Status (4)

Country Link
EP (1) EP0517754A1 (fr)
JP (1) JPH07507440A (fr)
CA (1) CA2077348A1 (fr)
WO (1) WO1991013166A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2095836C (fr) * 1990-11-09 1999-04-06 Stephen D. Gillies Immunoconjugues de la cytokine
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
EP1042459A4 (fr) * 1997-12-24 2003-07-23 Diatech Pty Ltd Molecules bifonctionnelles
US6617135B1 (en) 1999-08-09 2003-09-09 Emd Lexigen Research Center Corp. Multiple cytokine protein complexes
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
MXPA03008031A (es) * 2001-03-07 2003-12-04 Merck Patent Gmbh Tecnologia de expresion para proteinas que contienen porcion de anticuerpo isotipo hibrida.
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
US20050152894A1 (en) * 2003-09-05 2005-07-14 Genentech, Inc. Antibodies with altered effector functions
AU2005206277B2 (en) 2004-01-22 2011-06-23 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
EP2298815B1 (fr) 2005-07-25 2015-03-11 Emergent Product Development Seattle, LLC Reduction de lymphocytes B au moyen de molecules de liaison specifique de CD37 et specifique de CD20
ATE555125T1 (de) 2005-12-30 2012-05-15 Merck Patent Gmbh Interleukin-12p40-varianten mit verbesserter stabilität
ATE509954T1 (de) 2005-12-30 2011-06-15 Merck Patent Gmbh Anti-cd19-antikörper mit reduzierter immunogenität
KR101571027B1 (ko) 2006-06-12 2015-11-23 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 효과기 기능을 갖는 단일쇄 다가 결합 단백질
WO2009126944A1 (fr) 2008-04-11 2009-10-15 Trubion Pharmaceuticals, Inc. Produits d’immunothérapie de cd37 et combinaison avec un produit chimiothérapique bifonctionnel de celui-ci
EP2421896A1 (fr) 2009-04-22 2012-02-29 Merck Patent GmbH Protéines de fusion à des anticorps avec des sites de liaison à fcrn modifiés
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
SG10202002577XA (en) 2015-09-21 2020-04-29 Aptevo Res & Development Llc Cd3 binding polypeptides
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
EP3534947A1 (fr) 2016-11-03 2019-09-11 Kymab Limited Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340456C (fr) * 1986-07-07 1999-03-23 Hubert J.P. Schoemaker Immunoglobulines chimeriques de rongeur/homme specifiques pour antigenes associes a des tumeurs

Also Published As

Publication number Publication date
CA2077348A1 (fr) 1991-09-03
EP0517754A1 (fr) 1992-12-16
WO1991013166A1 (fr) 1991-09-05

Similar Documents

Publication Publication Date Title
JPH07507440A (ja) 結合親和性を高めた抗体構築物
US6174691B1 (en) Minimum recognition unit of a PEM mucin tandem repeat specific monoclonal antibody
Brown et al. Tumor-specific genetically engineered murine/human chimeric monoclonal antibody
US6071515A (en) Dimer and multimer forms of single chain polypeptides
Adams et al. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erb B-2 single-chain Fv
US5534254A (en) Biosynthetic binding proteins for immuno-targeting
Mueller et al. Serum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2.
US8617846B2 (en) Tumor-specific recognition molecules
Xu et al. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein
JP3492373B2 (ja) モノクローナル抗体
US20030147808A1 (en) Single Chain Fv constructs of anti-ganglioside GD2 antibodies
JPH09500381A (ja) トランスフェリン受容体特異的リガンド−神経作用剤融合タンパク質
US11642418B2 (en) Use of radiolabeled nanobody in prognosis and diagnosis of cancer
Crombet et al. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary study
US20070042447A1 (en) Use of anti-ferritin monoclonal antibodies in the treatment of some cancers (divisional)
US6737064B2 (en) Method for the diagnosis of neoplastic tissue comprising administering a vasopermeability enhancing peptide of human interleukin-2
US6534479B1 (en) Recombinant alpha-fetoprotein hybrid cytotoxins for treating and diagnosing cancers
US20190023785A1 (en) MONOCLONAL ANTIBODY FnAb8 AND APPLICATION THEREOF
TWI602577B (zh) 雙重標靶融合蛋白
Li et al. Development and characterization of the recombinant human VEGF-EGF dual-targeting fusion protein as a drug delivery system
JP2004507205A (ja) Ca19−9抗原陽性細胞の検出および除去のためのポリペプチド
US6440386B1 (en) Stabilized radiophosphate-labeled proteins
AU644413B2 (en) Antibody constructs with enhanced binding affinity
ES2218717T3 (es) Peptido portenciador de la vasopermeabilidad de la interleuquina-2 humana e inmunoconjugados del mismo.
US20040156824A1 (en) Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof